China-based Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that its minority-owned subsidiary, Xuanzhu Biopharmaceutical Co., Ltd, has obtained clinical trial approvals for two in-house developed drugs: CD80 mutant Fc fusion protein XZP-KM602 and DNA dependent protein kinase (DNA-PK) inhibitor XZP-6877. Both drugs are aimed at treating advanced solid tumors.
XZP-KM602: A Promising Fusion Protein for Enhancing T Cell Activation
XZP-KM602 is a fusion protein composed of an engineered extracellular domain of human CD80 and the Fc domain of human IgG1. It largely maintains the structure of natural CD80 and has low immunogenicity. XZP-KM602 can enhance the activation of effector T cells by inhibiting PD-L1 and CTLA-4 while promoting the co-stimulation of CD28, thereby exhibiting stronger antitumor activity. KM602 also possesses immune and memory functions, sustaining its anti-tumor activity. Pre-clinical studies have demonstrated that KM602 has significantly better antitumor efficacy than anti PD-L1, anti CTLA4 immune checkpoint drugs, and FPT155, a similar product developed by Five Prime Therapeutics, which is currently in Phase I clinical stage.
XZP-6877: A DNA-PK Inhibitor to Improve Cancer Treatment Sensitivity
XZP-6877 can block the main channels for DNA double strand breaks (DSBs) repair caused by radiotherapy and chemotherapy drugs, thereby improving the sensitivity of tumor cells to these treatments. Additionally, it destroys the stability of the DNA telomere structure to inhibit the proliferation and growth of tumor cells. As the first DNA-PK inhibitor in China, XZP-6877 holds a leading position in research and development progress and technical advantages. Preclinical data show that XZP-6877 has good druggability.-Fineline Info & Tech
